NCT00904423终止1 期
A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.
Mark Pegram1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2009年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Spine Bone Mineral Density T Score Change Over One Year
研究概览
简要总结
Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include bone loss, fractures, arthralgias and myalgias. We hypothesize vitamin D administration might be beneficial in treating these symptoms and to protect bone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •3.1.1 All postmenopausal women with histology-confirmed invasive primary breast cancer, who have completed primary surgical or radiotherapy (XRT) with or without adjuvant chemotherapy and are candidates to receive adjuvant therapy with aromatase inhibitors will be screened for eligibility. Postmenopausal is defined as satisfying one or more of the following criteria: having had bilateral oophorectomy; aged more than 60 years; or aged 55-59 years with an intact uterus and amenorrheic for at least 12 months; or if amenorrheic for less than 12 months (after receiving hysterectomy, hormone therapy or chemotherapy).
- •3.1.2 At the time of study enrollment, participants will have completed primary surgical or XRT with or without adjuvant chemotherapy. Chemotherapy will be completed at least 28 days prior to enrollment.
- •3.1.4 Participants will be women between 18-85 years of age. Women and minorities will be actively recruited. Though breast cancer extremely rarely occurs in children and men, this study will only recruit adult females.
- •3.1.5 Participants will have a life expectancy of at least 5 years.
- •3.1.6 Participants will have Eastern Clinical Oncology Group (ECOG) performance status 0-
- •3.1.7 Ability to understand and the willingness to sign a written informed consent document
排除标准
- •3.2.1 Medications affecting bone metabolism (bisphosphonates, anticonvulsants, chronic heparin therapy, chronic glucocorticoid use > 5 mg/day prednisone or equivalent, teriparatide).
- •3.2.2 Use of any investigational drug within past 90 days.
- •3.2.3 Metastatic breast cancer. High risk for osteoporosis/fractures (BMD < -2.0, history of non-traumatic fracture). Hyperparathyroidism Hypercalcemia Hypercalciuria (fasting spot urine calcium/creatinine ratio >0.20) History of renal stones Renal failure with creatinine over 2.0
- •3.2.4 Considering that vitamin D3 is produced by the human body, allergy to vitamin D3 is not expected to develop. Subjects with known history of allergic reaction to compounds used to manufacture capsules (rice powder) will be excluded form this study.
- •3.2.5 Recent history of excessive alcohol or drug use.
- •3.2.6 As this study will recruit post-menopausal patients, thus pregnant or nursing patients are not part of this investigation.
- •3.2.8 This study is designed to study women after completing primary therapy for breast cancer. Survivors of previous cancers and HIV-positive subjects will not be excluded.
研究组 & 干预措施
Vitamin D
Experimental
干预措施: Vitamin D (Drug)
结局指标
主要结局
Spine Bone Mineral Density T Score Change Over One Year
时间窗: 1 year
次要结局
- Change in Hip Bone Mineral Density (BMD) T-score(one year)
- Bone Turnover Markers(months 4 and 12)
- Arthralgias and Myalgias(every 4 months)
- Serum Calcium and Fasting Spot Urine Calcium/Creatinine Ratio(every 4 months)
研究者
Mark Pegram
Susy Yuan-Huey Hung Professor
Stanford University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy VolunteersMenstruation DisordersNCT00467493Meditrina Pharmaceuticals64
已完成
不适用
Anastrozole and LetrozoleBreast CancerNCT00762294UConn Health25
Unknown
不适用
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast CancerCarcinoma Breast Stage IVNCT02161315Tianjin Medical University Cancer Institute and Hospital80
已完成
2 期
Letrozole in Preventing Breast Cancer in Postmenopausal WomenBreast CancerNCT00090857Dana-Farber Cancer Institute49
已完成
不适用
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast CancerBreast CancerNCT00719966Mayo Clinic109